Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation

Journal of Investigative Dermatology

Volumn 129, Issue 10, 2009, Pages 2451-2462

  Bluth, Mark J ^a   Zaba, Lisa C ^b   Moussai, Dariush ^a   Suárez Farĩas, Mayte ^b   Kaporis, Helen ^b   Fan, Linda ^a   Pierson, Katherine C ^b   White, Traci R ^b   Pitts Kiefer, Alexander ^a   Fuentes Duculan, Judilyn ^b   Guttman Yassky, Emma ^b   Krueger, James G ^b   Lowes, Michelle A ^b   Carucci, John A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; LYMPHOCYTE PROLIFERATION; MICROENVIRONMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

ANTIGENS, CD1; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; HLA-DR ANTIGENS; HUMANS; LANGERHANS CELLS; LECTINS, C-TYPE; MEMBRANE GLYCOPROTEINS; NEOPLASMS, SQUAMOUS CELL; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, IMMUNOLOGIC; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349087826     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.96     Document Type: Article

References (58)

1. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM et al. (2000) Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 165:6723-6730
2. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD et al. (2002) VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62:4123-4131
3. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N et al. (2002) The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99:2929-2939
4. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24:302-306
5. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:2577-2587
6. Dauer M, Pohl K, Obermaier B, Meskendahl T, Robe J, Schnurr M et al. (2003) Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology 110:38-47
7. Dhodapkar MV, Krasovsky J, Olson K (2002) T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 99:13009-13013
8. Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309-316
9. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A (2007) Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9:461-467
10. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Whynot J, Novitskaya I, Cardinale I et al. (2007) Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 119:1210-1217
11. Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K, Chamian F et al. (2007) Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 178:7442-7449
12. Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J et al. (2006) Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 126:869-881
13. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B et al. (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478-6487
14. Huang FP, Niedbala W, Wei XQ, Xu D, Feng GJ, Robinson JH et al. (1998) Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol 28:4062-4070
15. Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H (2006) Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 15:1315-1319
16. Jeong HS, Lee H, Ko Y, Son YI (2007) Vaccinations with dendritic cells primed with apoptotic tumor cells can elicit preventive antitumor immunity in a poorly immunogenic animal model of squamous cell carcinoma. Laryngoscope 117:1588-1593
17. Kaporis HG, Guttman-Yassky E, Lowes MA, Haider AS, Fuentes-Duculan J, Darabi K et al. (2007) Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 127:2391-2398
18. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N et al. (2006) CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immun-other 55:1064-1071
19. Kusmartsev S, Gabrilovich DI (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174:4880-4891
20. Ladomery MR, Harper SJ, Bates DO (2007) Alternative splicing in angiogen-esis: the vascular endothelial growth factor paradigm. Cancer Lett 249:133-142
21. Larkin J, Tangney M, Collins C, Casey G, O'Brien MG, Soden D et al. (2006) Oral immune tolerance mediated by suppressor T cells may be responsible for the poorer prognosis of foregut cancers. Med Hypotheses 66:541-544
22. Le Naour F, Hohenkirk L, Grolleau A, Misek DE, Lescure P, Geiger JD et al. (2001) Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleo-tide microarrays and proteomics. J Biol Chem 276:17920-17931
23. Lee AW, Truong T, Bickham K, Fonteneau JF, Larsson M, Da Silva I et al. (2002) A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4):A8-22
24. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA (2002) Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol 14:1203-1213
25. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R et al. (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102:19057-19062
26. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al. (2008) Psoriasis Vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207-1211
27. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S et al. (2008) IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118:597-607
28. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H (2007) Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immun-other 56:761-770
29. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233-4244
30. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332
31. Nestle FO, Banchereau J, Hart D (2001) Dendritic cells: on the move from bench to bedside. Nat Med 7:761-765
32. Nickoloff BJ (2007) Cracking the cytokine code in psoriasis. Nat Med 13:242-244
33. O'Donnell RK, Mick R, Feldman M, Hino S, Wang Y, Brose MS et al. (2007) Distribution of dendritic cell subtypes in primary oral quamous cell carcinoma is inconsistent with a functional response. Cancer Lett 255:145-152
34. Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263-272
35. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R et al. (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57:1115-1124
36. Pospisilova D, Borovickova J, Polouckova A, Spisek R, Sediva A, Hrusak O et al. (2002) Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunol Immunother 51:72-78
37. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG (2003) TNF/ iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59-70
38. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835-1837
39. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204:1441-1451
40. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93:1634-1642
41. Steinman RM (2006) Linking innate to adaptive immunity through dendritic cells. Novartis Found Symp 279:101-9; discussion 109-113, 216-1109
42. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP (2007) GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 23:3251-3253
43. Talmadge JE (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13:5243-5248
44. Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26:373-400
45. Thomas CJ, Wood GC, Marks VJ (2007) Mohs micrographic surgery in the treatment of rare aggressive cutaneous tumors: the Geisinger experience. Dermatol Surg 33:333-339
46. van der Veen RC, Dietlin TA, Dixon Gray J, Gilmore W (2000) Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell Immunol 199:43-49
47. Vanacker A, Fabre G, Van Dorpe J, Peetermans WE, Maes B (2008) Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 8:877-880
48. Wang Q, Liu Y, Wang J, Ding G, Zhang W, Chen G et al. (2006) Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol 177:2175-2185
49. Weinberg AS, Ogle CA, Shim EK (2007) Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg 33:885-899
50. Wertel I, Barczynski B, Kotarski J (2008a) The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. Front Biosci 13:2177-2190
51. Wertel I, Polak G, Bednarek W, Barczynski B, Rolinski J, Kotarski J (2008b) Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom 74:251-258
52. Young MR, Lathers DM (1999) Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunophar-macol 21:241-252
53. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez Fariñas M, Fuentes-Duculan J et al. (2007a) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204:3183-3194
54. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC et al. (2008a) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129:79-88
55. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA (2007b) Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 117:2517-2525
56. Zaba LC, Krueger JG, Lowes MA (2009) Resident and " inflammatory" dendritic cells in human skin. J Invest Dermatol 129:302-308
57. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J et al. (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044-3048
58. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T et al. (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339-1346 (Pubitemid 34007939)